Recent developments include the Q3 2026 earnings report showing a net loss but revenue exceeding expectations, a strategic co-education partnership with Telix Pharma, and multiple earnings call disclosures throughout 2026.

• Profound Medical reported a net loss of $7.72 million and revenue of $9.83 million for Q3 2026, with EPS of -$0.21 per share [N1][S2].
• The company announced a co-education deal with Telix Pharma to advance PSMA-informed prostate care, indicating strategic collaboration efforts [N5].
• Q2 2026 earnings calls and reports highlighted revenue surpassing prior periods and ongoing clinical data presentations [N6][N7].
• The company’s liquidity position remains strong with $33.34 million in cash and a current ratio of 4.54 as of September 30, 2026 [S2].

The company’s recent revenue growth and strategic partnerships demonstrate progress in commercializing its medical technologies. Continued clinical data presentations and collaborations may enhance market adoption and brand recognition within the prostate care segment.

Profound Medical continues to report net losses, reflecting ongoing operational and development costs. The company faces risks typical of medical technology firms, including regulatory challenges, market adoption uncertainties, and competitive pressures. Liquidity, while currently strong, requires careful management to support ongoing operations and growth initiatives.

Profound Medical’s moat is derived from its specialized medical technology products and strategic collaborations, such as the co-education deal with Telix Pharma to advance PSMA-informed prostate care. The company’s focus on innovative prostate treatment technologies and clinical data presentations supports its competitive positioning in a niche medical market.

• Operational and Financial Risks: The company reports net losses and depends on managing liquidity effectively to fund operations and development [S2].
• Regulatory and Market Risks: Medical technology companies face regulatory approval processes and market adoption challenges that could impact business outcomes [S1][S2].
• Competitive Risks: Competition in the medical device and prostate care market may affect Profound Medical’s market share and pricing power.

• Profound Medical Corp. is a medical technology company with publicly available quarterly SEC filings as of 2026-09-30 [S2].
• The company reported revenue of $9.83 million for the quarter ending 2026-09-30 [S2].
• Net loss for the same period was $7.72 million, with basic and diluted EPS of -$0.21 per share [S2].
• As of 2026-09-30, the company held $33.34 million in cash and cash equivalents and had current assets of $54.83 million against current liabilities of $12.06 million, resulting in a current ratio of 4.54 and a cash ratio of 2.76 [S2].
• Recent news highlights include a Q3 loss report with revenue exceeding expectations, a co-education deal with Telix Pharma to advance PSMA-informed prostate care, and multiple earnings call transcripts and earnings reports throughout 2026 [N1][N5][N6][N7][N8].
• The company’s business risks are detailed in the 2025 Annual Report on Form 10-K filed on 2026-03-05, with no material changes reported in the latest 10-Q filing [S1][S2].